Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Article - 17/10/2018 Biologicals are becoming increasingly important to Boehringer Ingelheim Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Article - 08/08/2018 Ludolph: diagnosing and treating neurodegenerative disorders Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
Article - 26/06/2018 Genome analyses: "Germany lags behind dramatically" Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT. https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
Article - 19/03/2018 Regenerative medicine: curing rather than simply treating diseases Some scientists refer to the latest developments in the field of regenerative medicine as the "next revolution in medicine". With the help of gene therapies or stem cells, regenerative medicine aims not only to treat disease symptoms, but to cure them at source. Some approaches are already being used to treat patients and several others are close to application.https://www.gesundheitsindustrie-bw.de/en/article/news/regenerative-medicine-curing-rather-than-simply-treating-diseases
Article - 26/10/2016 GeneWerk: precision analyses for humans Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies. https://www.gesundheitsindustrie-bw.de/en/article/news/genewerk-precision-analyses-for-humans
Article - 08/08/2016 First achromatopsia gene therapy clinical trial in Germany is going well Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…https://www.gesundheitsindustrie-bw.de/en/article/news/first-achromatopsia-gene-therapy-clinical-trial-in-germany-is-going-well
Article - 19/07/2016 Licence to kill – the enormous potential of CAR T cells With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
Dossier - 14/06/2016 CRISPR/Cas – genome editing is becoming increasingly popular The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene editing or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary…https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
Article - 07/10/2015 Call for a moratorium on germ line experiments in humans Modern genetic engineering tools enable genes to be modified in a genomic context in living cells. Genome surgery unlocks enormous potential for the treatment of genetic diseases, but it could also be misused for the uncontrolled manipulation of the human genome. An interdisciplinary working group of German scientists is calling for a moratorium on human germ line experiments to provide a space to define the opportunities and risks of this new…https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-a-moratorium-on-germ-line-experiments-in-humans
Dossier - 10/11/2014 Cell and gene therapies: from bench to bedside While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
Article - 20/10/2014 First ever eye gene therapy close to clinical testing There are many different retinal diseases simply because many different steps of the visual process can be affected. However, they all have one thing in common: correction of the relevant defective gene currently provides the only possibility of permanent cure. Prof. Dr. Mathias Seeliger and his group of researchers at the Institute of Ophthalmic Research at the University Hospital in Tübingen is specifically focused on the development of gene…https://www.gesundheitsindustrie-bw.de/en/article/news/first-ever-eye-gene-therapy-close-to-clinical-testing
Article - 15/09/2014 Gene therapies for pulmonary disease are close to final development Gene therapy currently offers the only chance of curing genetic diseases such as cystic fibrosis and beta thalassaemia. Gene therapy is the replacement or correction of a mutated gene with DNA that encodes a functional gene. Intensive research has been going on in this field for many years however only a handful gene therapies are available at this point in time. Dr. Michael Kormann junior professor at the Childrens Hospital at the University of…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapies-for-pulmonary-disease-are-close-to-final-development
Press release - 20/08/2014 uniQure acquires HAE Accelerator Winner InoCard GmbH Heidelberg start-up develops gene therapy for the treatment of cardiac insufficiency. UniQure N.V. pays 3 million euros in cash and shares for the acquisition additional milestone payments and future revenue shares were agreed upon. https://www.gesundheitsindustrie-bw.de/en/article/press-release/uniqure-acquires-hae-accelerator-winner-inocard-gmbh
Article - 18/08/2014 The use of human genes as medical products In contrast to medications used for treating disease, gene therapy does not use chemical agents to alleviate or cure disease symptoms. Instead, it involves the introduction of a normal copy of a mutated gene to restore the function of a protein. Gene therapy could also be described as a way of restoring the body’s self-healing process. It is an extremely smart idea that enables the sustainable treatment of diseases which cannot usually be…https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-human-genes-as-medical-products
Article - 04/08/2014 Europe’s first gene therapy Scientists from the National Center for Tumour Diseases (NCT) have shown that adeno-associated viruses (AAV) do not pose a cancer risk. This conclusion is based on the analysis of several million patient cells treated with AAV and the finding that the viruses do not integrate into the patient genome. AAV is the first-ever gene therapy for clinical use in the Western world. AAV vectors could also potentially be used as prototypes for the treatment…https://www.gesundheitsindustrie-bw.de/en/article/news/europe-s-first-gene-therapy
Article - 28/07/2014 Successes and setbacks of clinical gene therapy The use of retroviral haematopoietic stem cell gene therapy to treat hereditary immunodeficiencies has achieved great success in resolving the actual symptoms of the disease, but many of the patients that underwent therapy developed leukaemia later. Effective gene therapies involving gene shuttles that do not cause cancer are therefore required. The good news is that such therapies already exist.https://www.gesundheitsindustrie-bw.de/en/article/news/successes-and-setbacks-of-clinical-gene-therapy
Article - 31/03/2014 The growing significance of peptide therapeutics The therapeutic use of peptides lags behind that of proteins. And there are good reasons for this. However, it seems that this is beginning to change and that peptide therapeutics are growing in significance. As a matter of fact, peptides have become rather popular candidates for drugs. https://www.gesundheitsindustrie-bw.de/en/article/news/the-growing-significance-of-peptide-therapeutics
Article - 18/11/2013 The HAE Accelerator – "compete to speed up your start-up" The HAE Accelerator is an international programme involving biomedical clusters in Cambridge (UK), Leuven (Belgium) and Heidelberg (Germany) that seeks to identify, train and put innovative start-up teams in the three countries in contact with international VC investors. Of the three business ideas that were awarded a HAE Investors’ Choice Award in September 2013, InoCard from Heidelberg came first with a new gene therapy for myocardial…https://www.gesundheitsindustrie-bw.de/en/article/news/the-hae-accelerator-compete-to-speed-up-your-start-up
Dossier - 01/04/2013 Retroviruses: from infectious agent to therapeutic assistant Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. Despite some similarities with accepted forms of life viruses are not considered as such. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV which leads to AIDS and for which no cure or effective vaccine is currently available. However retroviruses are not only of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/retroviruses-from-infectious-agent-to-therapeutic-assistant
Article - 18/12/2012 Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie? Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu
Press release - 20/08/2012 Viruses with integrated gene switch Scientists of the German Cancer Research Center (DKFZ) with colleagues from the University of Konstanz have developed “RNA switches” which allow them to specifically turn on and off genes in viruses. This will help to enhance regulation of gene therapy and viral therapy of cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/viruses-with-integrated-gene-switch
Press release - 03/08/2012 Rentschler and MHH sign licensing agreement for a gene therapy vector system The Hannover Medical School (MHH) and Rentschler Biotechnologie GmbH have signed a licensing agreement for the commercialization of a vector system for gene therapy that promises significant therapeutic and economic advantages over conventional technologies. Rentschler, an experienced specialist in the development of cell culture-based manufacturing processes and the production of relevant biopharmaceuticals, attains the right to develop…https://www.gesundheitsindustrie-bw.de/en/article/press-release/rentschler-and-mhh-sign-licensing-agreement-for-a-gene-therapy-vector-system